Furkan Bahar/X
Aug 3, 2026, 12:30
Furkan Bahar: Thrombotic and Hemorrhagic Risk Profiles in Advanced Melanoma – Targeted vs Immune Combination Therapies
Furkan Bahar, Research Fellow at Dana Farber, shared a post on X about a recent article he and his colleagues co-authored, published in RPTH, adding:
“Excited to share our new paper, published in Research and Practice in Thrombosis and Haemostasis!
We compared VTE and bleeding risk between BRAF/MEK inhibitors and ipilimumab/nivolumab combination therapy in patients with advanced melanoma.”
Title: Venous Thromboembolism and Bleeding in Advanced Melanoma: A Propensity-Matched Cohort Analysis Comparing First-Line Immunotherapy and Targeted Therapy
Authors: Furkan Bahar, Lauren O’Loughlin, Soravis Osataphan, Hollis Viray, Reed E. Drews, Rushad Patell
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?